Transoral robotic resection and reconstruction for head and neck cancer
- 25 July 2011
- journal article
- Published by Wiley in The Laryngoscope
- Vol. 121 (8), 1668-1674
- https://doi.org/10.1002/lary.21845
Abstract
Objectives/Hypothesis: To evaluate the patterns of failure, survival, and functional outcomes for patients treated with transoral robotic surgery (TORS) and compare these results with those from a cohort of patients treated with concurrent chemoradiation (CRT). Study Design: Prospective non‐randomized case control study. Methods: Between April 2007 and April 2009, 30 patients with head and neck squamous cell carcinoma were treated with primary TORS and adjuvant therapy as indicated on an institutional review board–approved protocol. Patients were evaluated before treatment, after treatment, and at subsequent 3‐month intervals after completing treatment to determine their disease and head and neck–specific functional status using the Performance Status Scale for Head and Neck Cancer and the Functional Oral Intake Score (FOIS). Functional scores were compared to a matched group of head and neck patients treated with primary CRT. Results: The TORS patient population included 73% stage III‐IV and 23% nonsmokers. The median follow‐up was 20.4 months (range, 12.8–39.6 months). The 18‐month locoregional control, distant control, disease‐free survival, and overall survival were 91%, 93%, 78%, and 90%, respectively. Compared to the primary CRT group, TORS was associated with better short‐term eating ability (72 vs. 43, P = .008), diet (43 vs. 25, P = .01), and FOIS (5.5 vs. 3.3, P < .001) at 2 weeks after completion of treatment. In contrast to TORS patients who returned to baseline, the CRT group continued to have decreased diet (P = .03) and FOIS (P = .02) at 12 months. Conclusions: Our early experience in treating selected head and neck cancers with TORS is associated with excellent oncologic and functional outcomes that compare favorably to primary CRT.Keywords
This publication has 34 references indexed in Scilit:
- Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)Head & Neck, 2009
- A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Squamous cell carcinoma of the oropharynxCancer, 2002
- Surgical treatment of squamous cell carcinoma of the base of tongueHead & Neck, 2001
- Radiation Therapy for Squamous Cell Carcinoma of the Tonsillar Region: A Preferred Alternative to Surgery?Journal of Clinical Oncology, 2000
- Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcomeInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Surgical management of squamous cell carcinoma of the base of the tongueThe American Journal of Surgery, 1993
- Base of tongue carcinoma: Patterns of failure and predictors of recurrence after surgery aloneHead & Neck, 1993
- Carcinoma of the Tonsillar Fossa: An UpdateJAMA Otolaryngology–Head & Neck Surgery, 1989
- Combined radiation therapy and surgery in the management of advanced head and neck cancer: Final report of study 73–03 of the radiation therapy oncology groupHead & Neck Surgery, 1987